Mercaptopurin Silver (Mercaptopurine Monohydrate)

After oral intake, mercaptopurine is metabolised inside cells to thioinosine monophosphate, which blocks the synthesis of new purine nucleotides. This disruption prevents DNA and RNA formation, leading to selective cytotoxicity of fast‑dividing malignant or immune cells.

The dosage of Mercaptopurin Silver is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and therapeutic response. Only a qualified health professional should determine the appropriate regimen.

Mercaptopurin Silver is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be used in pregnancy only when the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercaptopurin Silver belongs to the thiopurine class, offering an oral alternative to intravenous chemotherapy agents. Compared with newer targeted therapies, it is less expensive but may have a broader toxicity profile, requiring regular monitoring of blood counts and liver function.

Mercaptopurin Silver should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining a stable room‑temperature environment helps preserve the tablet’s potency throughout its shelf life.

The product is taken orally, usually with water. The exact timing relative to meals and other medications is determined by the prescriber to optimise absorption and minimize interactions.

The most serious risks include bone‑marrow suppression leading to severe anemia, neutropenia or thrombocytopenia, life‑threatening infections, and hepatotoxicity. Patients should be monitored closely for signs of infection, bleeding or liver dysfunction.

Mercaptopurin Silver is contraindicated in patients with known hypersensitivity to mercaptopurine or any component of the formulation, in those with severe hepatic impairment, and in pregnant women unless the therapeutic benefit outweighs the fetal risk. It should also be avoided in individuals with active, uncontrolled infections.